Abstract

People with subjective cognitive decline (SCD) and amnestic mild cognitive impairment (aMCI) are both at high risk for Alzheimer’s disease (AD). Behaviorally, both SCD and aMCI have subjective reports of cognitive decline, but the latter suffers a more severe objective cognitive impairment than the former. However, it remains unclear how the brain develops from SCD to aMCI. In the current study, we aimed to investigate the topological characteristics of the white matter (WM) network that can successfully identify individuals with SCD or aMCI from healthy control (HC) and to describe the relationship of pathological changes between these two stages. To this end, three groups were recruited, including 22 SCD, 22 aMCI, and 22 healthy control (HC) subjects. We constructed WM network for each subject and compared large-scale topological organization between groups at both network and nodal levels. At the network level, the combined network indexes had the best performance in discriminating aMCI from HC. However, no indexes at the network level can significantly identify SCD from HC. These results suggested that aMCI but not SCD was associated with anatomical impairments at the network level. At the nodal level, we found that the short-path length can best differentiate between aMCI and HC subjects, whereas the global efficiency has the best performance in differentiating between SCD and HC subjects, suggesting that both SCD and aMCI had significant functional integration alteration compared to HC subjects. These results converged on the idea that the neural degeneration from SCD to aMCI follows a gradual process, from abnormalities at the nodal level to those at both nodal and network levels.

Highlights

  • The current status of Alzheimer’s disease (AD) clinical treatment is not promising, which makes preclinical prediction for AD important (Huang et al, 2020)

  • MMSE was significantly higher in healthy control (HC) than in subjective cognitive decline (SCD) and amnestic mild cognitive impairment (aMCI)

  • Memory and executive functions declined in the order of HC, SCD, and aMCI

Read more

Summary

Introduction

The current status of Alzheimer’s disease (AD) clinical treatment is not promising, which makes preclinical prediction for AD important (Huang et al, 2020). Characterized by objective cognitive impairment similar to AD, mild cognitive impairment has been proposed as an important stage in the development of AD. About one-third of those with amnesiac mild cognitive impairment (aMCI) will develop AD within 5 years (Ward et al, 2013). The elderly with subjective cognitive decline (SCD) has a high risk for developing AD (Jessen et al, 2020). Both at the early stages of AD, the major behavioral difference between SCD and aMCI is that aMCI has severer objective cognitive impairments than SCD. Knowledge about the relationship between SCD and aMCI neuroimaging characteristics is still insufficient

Objectives
Methods
Results
Conclusion

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.